All In Biotech

Drug Trial Radar · NCT03249337

Glanatec(R) for Descemet Stripping in Fuch's Endothelial Dystrophy

A Pilot Study For Efficacy And Safety Of Glanatec® Opthalmic Solution 0.4% On Corneal Edema And Endothelial Cell Counts In Subjects With Fuchs Endothelial Dystrophy Undergoing Descemet Stripping Without Endothelial Keratoplasty

Last checked: Nov 19, 2026Latest source record: Aug 11, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Dec 6, 2017

Primary completion

Dec 2021

Study completion Dec 2021

Sponsor

Lead sponsor
Marian Macsai, MDAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 15, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 91 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In brief, the objective of this study is to investigate whether the drug Glanatec ® which is approved in Japan for glaucoma and ocular hypertension, can be used in patients with Fuchs endothelial dystrophy who have had a descemet stripping procedure without endothelial keratoplasty. While some limited data exists as a proof of concept in in vitro or animal studies, and Glanatec® has been successfully used in a recently published case series for this indication, there is insufficient data to show that this drug can be effectively used for corneal cell clearing while maintaining patient safety. The goal of the study is to provide sufficient proof of concept for the use of this drug in patients with FED whose only treatment alternative is to undergo corneal transplant.

Conditions

  • Fuchs' Endothelial Dystrophy

Interventions

  • Ripasudil hydrochloride hydrate 0.4% ophthalmic solutionDrug

    the ophthalmic solution will be administered three or six per times per day in the eye designated as the "Study Eye" upon study enrollment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Corneal ClearingTime frame: 12 months
  2. pachymetry measurementTime frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • NorthShore University HealthSystem

    Glenview, Illinois · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.